¼¼°èÀÇ Ç÷¾× ±â¹Ý ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå º¸°í¼­(2025³â)
Blood Based Biomarkers Global Market Report 2025
»óǰÄÚµå : 1760490
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,233,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,010,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,786,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Ç÷¾× ±â¹Ý ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â µ¿¾È 12.4%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü·Î 2029³â±îÁö 415¾ï 5,000¸¸ ´Þ·¯ ±Ô¸ð·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾ÈÀÇ ¼ºÀåÀº ¹ÙÀÌ¿À¸¶Ä¿ ºÐ¼®¿¡¼­ AI ¹× ¸Ó½Å·¯´×ÀÇ È®´ë, Áúº´ Á¶±â ¹ß°ß¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ¿ø°ÝÀÇ·á ¹× ¿ø°Ý Áø´ÜÀÇ ¼ºÀå, ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡, ¼ÒºñÀÚÀÇ °Ç°­ ÀÎ½Ä Áõ°¡¿¡ ÀÇÇØ ÁÖµµµÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÀÌ ±â°£ÀÇ ÁÖ¿ä µ¿ÇâÀ¸·Î´Â AI¸¦ Ȱ¿ëÇÑ ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö, ¾×ü »ý°ËÀÇ ¹ßÀü, ¸ÖƼ¿À¹Í½º ÅëÇÕ, ÇöÀåÁø´Ü(POC) °Ë»ç±â±â °³¹ß, Â÷¼¼´ë ¿°±â¼­¿­ºÐ¼®(NGS) Çõ½Å µîÀÌ ÀÖ½À´Ï´Ù.

½ÉÇ÷°üÁúȯÀÇ À¯º´·ü Áõ°¡´Â Ç÷¾× ±â¹Ý ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÉÇ÷°üÁúȯÀº °ü»óµ¿¸ÆÁúȯ, ½ÉºÎÀü, ³úÁ¹Áß µî ½ÉÀå°ú Ç÷°ü¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁúȯÀ» Æ÷ÇÔÇϸç, ½Ä½À°ü Àå¾Ö ¹× ºñ¸¸À² Áõ°¡¿Í °°Àº À§Çè ¿äÀÎÀ¸·Î ÀÎÇØ ´õ¿í º¸ÆíÈ­µÇ°í ÀÖ½À´Ï´Ù. Ç÷¾× ±â¹Ý ¹ÙÀÌ¿À¸¶Ä¿´Â Ç÷¾× ³» ÃøÁ¤ °¡´ÉÇÑ ¹°ÁúÀ» ÅëÇØ Áúº´ÀÇ ÁøÇà, À§Çè Æò°¡, Ä¡·á ¹ÝÀÀ¿¡ ´ëÇÑ ±ÍÁßÇÑ Á¤º¸¸¦ Á¦°øÇÔÀ¸·Î½á ÀÌ·¯ÇÑ Áúº´ÀÇ Áø´Ü ¹× ¸ð´ÏÅ͸µ¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. 2024³â 9¿ù ±¹¸³»ý¸í°øÇÐÁ¤º¸¼¾ÅÍ(National Center for Biotechnology Information)°¡ ½Ç½ÃÇÑ ¼¼°è °Ç°­ Á¶»ç ÀÌ´Ï¼ÅÆ¼ºê¿¡ µû¸£¸é 2025-2050³â±îÁö ½ÉÇ÷°ü Áúȯ ȯÀÚ°¡ 90% Áõ°¡Çϰí, ½ÉÇ÷°ü ÁúȯÀ¸·Î ÀÎÇÑ »ç¸ÁÀÚ ¼ö´Â 2050³â±îÁö 3,560¸¸ ¸í¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÉÇ÷°üÁúȯÀÇ À¯º´·ü Áõ°¡°¡ Ç÷¾× ±â¹Ý ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

Ç÷¾× ±â¹Ý ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷µéÀº ¾ËÃ÷ÇÏÀ̸Ӻ´ µîÀÇ Áø´Ü¿¡ µµ¿òÀÌ µÇ´Â °íÁ¤¹Ð Ç÷¾× ¹ÙÀÌ¿À¸¶Ä¿ °Ë»ç¿Í °°Àº ±â¼ú Çõ½Å¿¡ ÁýÁßÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °Ë»ç´Â Ç÷¾× ³» ƯÁ¤ ¹ÙÀÌ¿À¸¶Ä¿¸¦ Ȱ¿ëÇÏ¿© ³ôÀº Á¤È®µµ¿Í ½Å·Ú¼ºÀ¸·Î °Ç°­ »óŸ¦ °¨ÁöÇϰųª ¸ð´ÏÅ͸µÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹ »ý¸í°úÇÐ ±â¾÷ ÄöÅ׸¯½º(Quanterix)´Â 2023³â 10¿ù, Àǻ簡 ÀÎÁö±â´É Àå¾Ö°¡ ÀÖ´Â ¼ºÀÎÀÇ ¾ËÃ÷ÇÏÀ̸Ӻ´ Áø´ÜÀ» µ½±â À§ÇØ °í¾ÈµÈ °íÁ¤¹Ð Ç÷¾× ¹ÙÀÌ¿À¸¶Ä¿ °Ë»çÀÎ LucentAD p-Tau 217 °Ë»ç¸¦ ¹ßÇ¥ÇÏ¿´½À´Ï´Ù. ÀÌ °Ë»ç´Â ¾ËÃ÷ÇÏÀ̸Ӻ´ÀÇ º´ÅÂ, ƯÈ÷ ³ú ³» ¾Æ¹Ð·ÎÀ̵å ÃàÀû°ú ¹ÐÁ¢ÇÑ ¿¬°üÀÌ ÀÖ´Â Æ®·¹¿À´Ñ 217·Î ÀλêÈ­ µÈ Ÿ¿ì ´Ü¹éÁú(p-Tau 217)À» ÃøÁ¤ÇÏ´Â °Ë»ç·Î, 90% ÀÌ»óÀÇ Á¤È®µµ¸¦ Á¦°øÇϸç, ¾ö°ÝÇÑ Áø´Ü ±âÁØÀ» ÃæÁ·ÇÏ´Â °Ë»çÀÔ´Ï´Ù. ´Üµ¶ÀÌ ¾Æ´Ñ ´Ù¸¥ Áø´Ü µµ±¸¿Í º´ÇàÇÏ¿© »ç¿ëÇϵµ·Ï µÇ¾î ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ª ÀüÀï°ú °ü¼¼, ±×¸®°í Äڷγª¿Í ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°¡¤±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷°ú Çõ½ÅÀû ±â¾÷

Á¦32Àå ¼¼°èÀÇ ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´

Á¦34Àå ÃÖ±ÙÀÇ ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀå ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Blood-based biomarkers are substances in the blood that can be measured to indicate the presence, progression, or response to a disease. They are primarily used for early detection, helping to personalize treatment plans and monitor treatment effectiveness with minimal invasiveness.

These biomarkers can be categorized into several types, including genetic, protein, metabolic, cell-based, and epigenetic biomarkers. Genetic biomarkers, which are based on DNA or RNA, identify genetic variations, mutations, or expression patterns linked to specific diseases or treatment responses. They are utilized in various advanced technologies, such as next-generation sequencing, polymerase chain reaction, immunoassays, and mass spectrometry. These biomarkers play a critical role in diagnosing and monitoring diseases such as cancer, cardiovascular conditions, neurological disorders, and immunological diseases. Key users of these biomarkers include hospitals, clinics, diagnostic labs, research institutes, and other healthcare providers.

The blood-based biomarkers market research report is one of a series of new reports from The Business Research Company that provides blood-based biomarkers market statistics, including the blood-based biomarkers industry global market size, regional shares, competitors with the blood-based biomarkers market share, detailed blood-based biomarkers market segments, market trends, and opportunities, and any further data you may need to thrive in the blood-based biomarkers industry. This blood-based biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The blood-based biomarkers market size has grown rapidly in recent years. It will grow from $23.13 billion in 2024 to $26.06 billion in 2025 at a compound annual growth rate (CAGR) of 12.6%. The growth observed in the past can be attributed to the increasing global incidence of cancer, a higher adoption of personalized medicine, more funding in biomarker research, a rise in clinical trials involving biomarkers, and an increase in the approval of companion diagnostics.

The blood-based biomarkers market size is expected to see rapid growth in the next few years. It will grow to $41.55 billion in 2029 at a compound annual growth rate (CAGR) of 12.4%. The growth during the forecast period is expected to be driven by the expansion of AI and machine learning in biomarker analysis, a higher demand for early disease detection, the growth of telemedicine and remote diagnostics, the increasing prevalence of chronic diseases, and greater health awareness among consumers. Key trends during this period will include AI-driven biomarker discovery, advancements in liquid biopsy, integration of multi-omics, development of point-of-care (POC) testing devices, and innovations in next-generation sequencing (NGS).

The increasing prevalence of cardiovascular diseases is expected to drive the growth of the blood-based biomarkers market. Cardiovascular diseases, which encompass disorders affecting the heart and blood vessels such as coronary artery disease, heart failure, and stroke, are becoming more common due to risk factors such as poor diet and rising obesity rates. Blood-based biomarkers play a crucial role in diagnosing and monitoring these diseases by offering valuable information on disease progression, risk assessment, and treatment response through measurable substances in the blood. A global health research initiative by the National Center for Biotechnology Information in September 2024 projected a 90% increase in cardiovascular disease cases from 2025 to 2050, with cardiovascular deaths expected to reach 35.6 million by 2050. This rising incidence of cardiovascular diseases is contributing to the market growth for blood-based biomarkers.

Leading companies in the blood-based biomarkers market are focusing on technological innovations, such as high-accuracy blood biomarker tests, to assist in diagnosing diseases such as Alzheimer's disease. These tests use specific biomarkers in the blood to detect or monitor health conditions with high precision and reliability. For example, in October 2023, Quanterix, a US-based life sciences company, introduced the LucentAD p-Tau 217 test, a high-accuracy blood biomarker test designed to help physicians diagnose Alzheimer's disease in adults with cognitive impairment. The test measures phosphorylated tau protein at threonine 217 (p-Tau 217), which is strongly linked to Alzheimer's pathology, particularly amyloid buildup in the brain. The LucentAD p-Tau 217 test provides over 90% accuracy, fulfilling stringent diagnostic criteria, and is meant to be used alongside other diagnostic tools rather than independently.

In December 2023, Danaher, a US-based provider of diagnostic, life sciences, and environmental solutions, acquired Abcam for $5.7 billion. This acquisition allows Danaher to enhance its life sciences portfolio by incorporating Abcam's leading protein consumables and research tools. Abcam, a UK-based life sciences company, specializes in the development and distribution of research tools, including antibodies, assays, and reagents.

Major players in the blood based biomarkers market are Siemens Healthineers AG, Agilent Technologies Inc, Eisai Co Ltd, Sysmex Corporation, Exact Sciences Corporation, Guardant Health, Quanterix Corporation, Illumina Inc, QIAGEN NV, GENFIT, Foundation Medicine Inc, Adaptive Biotechnologies Corporation, GRAIL LLC, Biodesix Inc, Cleveland Diagnostics Inc, Creative Diagnostics, Epigenomics AG, C2N Diagnostics, Diadem srl, Proteomedix AG.

North America was the largest region in the blood-based biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in blood-based biomarkers report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the blood-based biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The blood-based biomarkers market consists of revenues earned by entities by providing services such as clinical trial services, sample collection and biobanking services, custom biomarker assay development, data analysis and interpretation services, companion diagnostics services, point-of-care testing services, and regulatory and compliance support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The blood-based biomarkers market includes sales of diagnostic kits, reagents, assay platforms, analyzers, and related consumables. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Blood Based Biomarkers Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on blood based biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for blood based biomarkers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The blood based biomarkers market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Blood Based Biomarkers Market Characteristics

3. Blood Based Biomarkers Market Trends And Strategies

4. Blood Based Biomarkers Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Blood Based Biomarkers Growth Analysis And Strategic Analysis Framework

6. Blood Based Biomarkers Market Segmentation

7. Blood Based Biomarkers Market Regional And Country Analysis

8. Asia-Pacific Blood Based Biomarkers Market

9. China Blood Based Biomarkers Market

10. India Blood Based Biomarkers Market

11. Japan Blood Based Biomarkers Market

12. Australia Blood Based Biomarkers Market

13. Indonesia Blood Based Biomarkers Market

14. South Korea Blood Based Biomarkers Market

15. Western Europe Blood Based Biomarkers Market

16. UK Blood Based Biomarkers Market

17. Germany Blood Based Biomarkers Market

18. France Blood Based Biomarkers Market

19. Italy Blood Based Biomarkers Market

20. Spain Blood Based Biomarkers Market

21. Eastern Europe Blood Based Biomarkers Market

22. Russia Blood Based Biomarkers Market

23. North America Blood Based Biomarkers Market

24. USA Blood Based Biomarkers Market

25. Canada Blood Based Biomarkers Market

26. South America Blood Based Biomarkers Market

27. Brazil Blood Based Biomarkers Market

28. Middle East Blood Based Biomarkers Market

29. Africa Blood Based Biomarkers Market

30. Blood Based Biomarkers Market Competitive Landscape And Company Profiles

31. Blood Based Biomarkers Market Other Major And Innovative Companies

32. Global Blood Based Biomarkers Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Blood Based Biomarkers Market

34. Recent Developments In The Blood Based Biomarkers Market

35. Blood Based Biomarkers Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â